Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006756048> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2006756048 endingPage "IA18" @default.
- W2006756048 startingPage "IA18" @default.
- W2006756048 abstract "Blockade of the programmed death (PD-1) checkpoint has emerged as a promising approach for immunotherapies in the treatment of non-small cell lung cancer (NSCLC). Immune checkpoints, such as PD-1, an inhibitory T-cell immunoreceptor, and the receptor9s ligands, PD-L1 and PD-L2, assist in hindering autoimmunity and protecting peripheral tissues to minimize damage (1). However, in cancers, the interaction between PD-1 and its ligands also can result in the promotion of an immunosuppressive tumor microenvironment (1). Several agents targeting PD-1 are currently undergoing clinical development. Clinical trials of anti-PD-1 antibodies nivolumab (BMS-936558) and MK-3475 have produced encouraging results in non-small cell lung cancer patients with regards to objective response rates (ORR) and progression free survival (PFS) (2,3). In a pretreated advanced NSCLC population, nivolumab produced durable responses, particularly at 3 and 10 mg/kg doses (2). For 38 previously-treated NSCLC patients, MK-3475, administered at 10 mg/kg every three weeks, led to an ORR of 24 percent based on irRC (21 percent based on RECIST 1.1) (3). Median overall survival was 51 weeks with a PFS, which had not been reached at a time when the minimum PFS would be 62 weeks among the responders (3). ORR was 67% in patients with tumors having PD-L1 expression above a cutpoint versus 4% in those below the cutpoint (3). Based on the favorable response rates relative to historical controls, and the durability of responses in clinical trials, the development of PD-1 inhibitors in lung cancer is proceeding rapidly. Future trials utilizing anti PD-1 antibodies will explore further biomarkers, and combination with other therapies. Citation Format: Edward B. Garon, Brian R. Wolf, Deborah JL Wong, Jonathan W. Goldman. Early but promising data: PD-1 inhibitors in non-small cell lung cancer. [abstract]. In: Proceedings of the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer; 2014 Jan 6-9; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2014;20(2Suppl):Abstract nr IA18." @default.
- W2006756048 created "2016-06-24" @default.
- W2006756048 creator A5036134937 @default.
- W2006756048 creator A5044848659 @default.
- W2006756048 creator A5058393482 @default.
- W2006756048 creator A5060287300 @default.
- W2006756048 date "2014-01-15" @default.
- W2006756048 modified "2023-09-27" @default.
- W2006756048 title "Abstract IA18: Early but promising data: PD-1 inhibitors in non-small cell lung cancer." @default.
- W2006756048 cites W2066671159 @default.
- W2006756048 doi "https://doi.org/10.1158/1078-0432.14aacriaslc-ia18" @default.
- W2006756048 hasPublicationYear "2014" @default.
- W2006756048 type Work @default.
- W2006756048 sameAs 2006756048 @default.
- W2006756048 citedByCount "0" @default.
- W2006756048 crossrefType "journal-article" @default.
- W2006756048 hasAuthorship W2006756048A5036134937 @default.
- W2006756048 hasAuthorship W2006756048A5044848659 @default.
- W2006756048 hasAuthorship W2006756048A5058393482 @default.
- W2006756048 hasAuthorship W2006756048A5060287300 @default.
- W2006756048 hasConcept C121608353 @default.
- W2006756048 hasConcept C126322002 @default.
- W2006756048 hasConcept C143998085 @default.
- W2006756048 hasConcept C159654299 @default.
- W2006756048 hasConcept C203014093 @default.
- W2006756048 hasConcept C2776256026 @default.
- W2006756048 hasConcept C2777701055 @default.
- W2006756048 hasConcept C2780030458 @default.
- W2006756048 hasConcept C2908647359 @default.
- W2006756048 hasConcept C535046627 @default.
- W2006756048 hasConcept C71924100 @default.
- W2006756048 hasConcept C99454951 @default.
- W2006756048 hasConceptScore W2006756048C121608353 @default.
- W2006756048 hasConceptScore W2006756048C126322002 @default.
- W2006756048 hasConceptScore W2006756048C143998085 @default.
- W2006756048 hasConceptScore W2006756048C159654299 @default.
- W2006756048 hasConceptScore W2006756048C203014093 @default.
- W2006756048 hasConceptScore W2006756048C2776256026 @default.
- W2006756048 hasConceptScore W2006756048C2777701055 @default.
- W2006756048 hasConceptScore W2006756048C2780030458 @default.
- W2006756048 hasConceptScore W2006756048C2908647359 @default.
- W2006756048 hasConceptScore W2006756048C535046627 @default.
- W2006756048 hasConceptScore W2006756048C71924100 @default.
- W2006756048 hasConceptScore W2006756048C99454951 @default.
- W2006756048 hasIssue "2 Supplement" @default.
- W2006756048 hasLocation W20067560481 @default.
- W2006756048 hasOpenAccess W2006756048 @default.
- W2006756048 hasPrimaryLocation W20067560481 @default.
- W2006756048 hasRelatedWork W2122517565 @default.
- W2006756048 hasRelatedWork W2318979033 @default.
- W2006756048 hasRelatedWork W2340296324 @default.
- W2006756048 hasRelatedWork W2667192089 @default.
- W2006756048 hasRelatedWork W2743614427 @default.
- W2006756048 hasRelatedWork W2799455970 @default.
- W2006756048 hasRelatedWork W2887843436 @default.
- W2006756048 hasRelatedWork W2889693176 @default.
- W2006756048 hasRelatedWork W2893469983 @default.
- W2006756048 hasRelatedWork W2944557198 @default.
- W2006756048 hasRelatedWork W2946119674 @default.
- W2006756048 hasRelatedWork W2955632382 @default.
- W2006756048 hasRelatedWork W2969124302 @default.
- W2006756048 hasRelatedWork W3009252808 @default.
- W2006756048 hasRelatedWork W3010492725 @default.
- W2006756048 hasRelatedWork W3094071864 @default.
- W2006756048 hasRelatedWork W3121945300 @default.
- W2006756048 hasRelatedWork W3170396007 @default.
- W2006756048 hasRelatedWork W3177627618 @default.
- W2006756048 hasRelatedWork W3181477964 @default.
- W2006756048 hasVolume "20" @default.
- W2006756048 isParatext "false" @default.
- W2006756048 isRetracted "false" @default.
- W2006756048 magId "2006756048" @default.
- W2006756048 workType "article" @default.